ISO 13485 Manufacturing Conditions under Regulation 19

1. Key takeaways

Article 19 of the Israeli Regulations provides that devices marketed in Israel must be manufactured in a plant that conforms to the ISO 13485 standard and that holds a certificate issued by the health authority or competent authority of the country of manufacture; for devices manufactured locally in Israel, ISO 13485 approval by an agency recognised by the Director is additionally required, together with a manufacturing business licence under the Business Licensing Law, 5728-1968. This requirement operates at the site level, not at the company level — the scope of the certificates must cover the actual production site, and outsourced processes such as sterilisation carry their own separate requirements.

• ISO 13485 conformity and a certificate from the manufacturing-country authority are cumulative requirements under Article 19, not alternatives.
• The obligation is site-level: a group certificate that does not name the actual production plant does not satisfy it.
• Outsourced sterilisation and other key processes need separate certificates from the outsourcing provider.
• Israeli local manufacturing adds a cross-cutting obligation under the Business Licensing Law, 5728-1968, administered separately from device regulation.

2. Legal basis

The production-condition requirements and their statutory context are set out below, including the provisions of the Regulations, the referenced licensing law and the parent Medical Equipment Law.

3. Expert insights

Article 19 stacks together two requirements of a different nature, and they are easily confused, so it is worth separating the layers before assembling the evidence.

The first layer is the quality management system (ISO 13485). This is an endorsement of the processes, typically issued by a notified body or an accredited certification body. The practical expectation is that the certificate is within its validity period and that its scope of certification covers the category of the device under application and the relevant activities — design and development, production, sterilisation and so on. A certificate whose scope schedule does not name the device category or the activity will invite questions even if the certificate itself is current.

The second layer is the certificate from the competent authority of the country of manufacture. This is an endorsement of the national regulatory system. Chinese companies usually evidence this layer by combining the Medical Device Manufacturing Licence with the product registration certificate. GRZAN’s practical estimate for handling this layer is that the materials should explain how the Chinese regulatory system controls the device category in question, with an English explanation attached where necessary, since the reviewer may not be familiar with the structure of the Chinese system.

The third layer (local manufacture only) is the business licence. Devices manufactured inside Israel additionally require a manufacturing business licence under the Business Licensing Law. This is an Israel-specific cross obligation, falling under a different competent authority from device regulation, and it is therefore easy to overlook when the project plan is built around the AMAR track alone; it must be confirmed with the local licensing authority rather than inferred from the device approval.

A frequent high-impact deficiency is a certificate scope that does not cover the site. Group companies producing at multiple sites often submit the ISO 13485 certificate of the group headquarters without covering the actual production site. Article 3(a)(3) of the Regulations expressly requires information on the manufacturer and the production site, and the two must correspond. Where the sterilisation outsourcing provider is not within the scope of the main certificate, its certificate must be provided separately. Because this evidence enters the application itself through Article 3(a)(3), a scope mismatch is not a post-registration finding but a submission-stage rejection risk, and the 1-month cooling-off consequence attaches to it exactly as it does to any other missing element of the dossier.

4. Practical recommendations

• Run a three-point check of certificate, site and product. The scope of the ISO 13485 certificate, the actual production site and the device category under application must all three match; any mismatch is a rejection risk.
• Evidence outsourced processes separately. Where sterilisation or other key processes are outsourced, provide the outsourcing provider’s certificate together with the quality agreement.
• Pair the manufacturing-country certificate with an explanation. Attach English explanatory material describing how the Chinese competent authority controls the device category.
• Align validity periods and renewals. Enter the ISO 13485 expiry date into the expiry-date board that is synchronised with the AMAR registration, so renewals are never left to the last moment and a lapsed certificate never sits underneath an active registration.

5. Verification checklist

• □ The ISO 13485 certificate is within its validity period and its scope covers the device category under application
• □ The certificate covers the actual production site (checked site by site for multi-site production)
• □ Certificates for outsourced sterilisation or other key processes have been provided separately
• □ The manufacturing-country competent authority certificate is ready and accompanied by an English explanation
• □ For the Israeli local manufacturing scenario, the business licence requirement has been confirmed (Article 19 plus the Business Licensing Law)
• □ Certificate expiry dates have been entered into the board synchronised with the AMAR registration

Regulatory information verified as of 29 October 2026. The regulation names, numbers, publication dates and provisions cited in this article were checked against the official Israeli legal databases and authoritative public sources on that date; AMAR procedural documents are updated frequently, so before any formal submission the current version on the Ministry of Health website prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Israeli market. Our team prepares MOH-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com